Abstract: There is provided a method of prevention of adhesions, eg surgical adhesions, which comprises using a vitamin D compound.

Abstract: There is provided a method of treatment of male sub-fertility by using a vitamin D compound. Compositions and uses are also provided.

Abstract: The invention provides for the use of Vitamin D compounds such as 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-chole-calciferol, in the prevention or treatment of prostate cancer.

Abstract: The invention provides for methods of using 20-methyl Gemini vitamin D3 compounds to treat osteoporosis and secondary hyperparathyroidism.

Abstract: The invention provides vitamin D3 analogs of cholecalciferol, substituted at carbons-26 and 27 with deuterated alkyl groups, e.g., trideuteromethyl, wherein carbon-16 is a single or double bond, and carbon-23 is a single, double, or triple bond. The invention provides pharmaceutically acceptable esters, salts, and prodrugs thereof. Methods for using the compounds to treat vitamin D3 associated states, and pharmaceutical compositions containing the compounds are also disclosed.

Abstract: The invention provides a method of producing 20-methyl vitamin D3 compounds of formula (I). The method includes allylic and olefin oxidation, de-carbonylation, carbonyl reduction, fluoride substitution, epoxide deoxygenation, and Wittig-type couplings.

Abstract: The present invention relates to a method of diagnosing bacterial or fungal sepsis in a subject, which method comprises the step of measuring the level of TREM-1-Ligand or TREM-1-Ligand nucleic acid in a biological sample obtained from said subject. The method can involve contacting said biological sample with a compound capable of binding TREM-1-Ligand and detecting the level of TREM-1-Ligand present in the sample by observing the level of binding between said compound and TREM-1-Ligand. Compounds, compositions and kits for use in the diagnosis of bacterial or fungal sepsis are also provided.

Abstract: The invention provides 20-alkyl Gemini vitamin D3 compounds, methods for using the compounds to treat vitamin D3 associated states and pharmaceutical compositions containing the compounds.

Abstract: The invention provides vitamin D3 analogs of cholecalciferol, substituted at carbon 20 with cycloalkyl, e.g., cyclopropyl, wherein carbon-16 is a double bond, and carbon-23 is a single, double, or triple bond. Various alkyl or haloalkyl substitutions are incorporated as carbon-25. The invention provides pharmaceutically acceptable esters, salts, and prodrugs thereof. Methods for using the compounds to treat vitamin D3 associated states, and pharmaceutical compositions containing the compounds are also disclosed.

Abstract: The invention provides Gemini vitamin D3 compounds, methods for using the compounds to treat vitamin D3 associated states and pharmaceutical compositions containing the compounds.

Abstract: The use of vitamin D compounds in the treatment or prevention of endometriosis, methods for the treatment or prevention of endometriosis by administering a vitamin D compound, and compounds for use therein.

Abstract: The use of 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol, or a pharmaceutically acceptable salt or ester thereof, for the manufacture of a medicament for the prevention and/or treatment of benign prostatic hyperplasia (BPH) and associated symptoms.

Abstract: The invention provides (1,3)di-acylated vitamin D3 analogs of cholecalciferol, substituted at carbon (20) with methyl or cyclopropyl wherein carbon (16) is a single or double bond, and carbon (23) is a single, double, or triple bond. Various alkyl or haloalkyl substitutions are incorporated at carbon (25). The invention provides pharmaceutically acceptable esters, salts, and pro-drugs thereof. Methods for using the compounds to treat vitamin D3 associated states, and pharmaceutical compositions containing the compounds are also disclosed.

Abstract: The use of 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol, or a pharmaceutically acceptable salt or ester thereof, for the manufacture of a medicament for the prevention and/or treatment of benign prostatic hyperplasia (BPH) and associated symptoms.

Abstract: There is provided according to the invention a vitamin D compound for use in the prevention and/or treatment of interstitial cystitis. Also provided is a method for preventing and/or treating interstitial cystitis by administering an effective amount of a vitamin D compound.

Abstract: There is provided according to the invention the use of Vitamin D compounds such as 1-alpha-fluoro-25-hydroxy-16,23e-diene-26,27-bishomo-20-epi-cholecalciferol in the prevention or treatment of bladder dysfunction.

Abstract: The invention provides 1,3 acylated, 24-keto vitamin D3 compounds of formula I: wherein: X1 and X1 are each independently H2 or ?CH2, provided X1 and X1 are not both ?CH2; R1 and R2 are each independently, hydroxyl, OC(O)C1-C4 alkyl, OC(O)hydroxyalkyl, OC(O)haloalkyl, provided that R1 and R2 are not both hydroxyl; R3 and R4 are each independently hydrogen, C1-C4 alkyl, hydroxyalkyl, or haloalkyl, or R3 and R4 taken together with C20 form C3-C6 cylcoalkyl; and R5 and R6 are each independently C1-C4 alkyl, hydroxyalkyl, or haloalkyl; and pharmaceutically acceptable esters, salts, and prodrugs thereof. Methods for using the compounds to treat vitamin D3 associated states, and phar,aceutical compositions containing the compounds are also disclosed.

Abstract: The invention provides 1,3-di-acylated vitamin D3 analogs of cholecalciferol, substituted at carbon-20 with methyl or cyclopropyl wherein carbon-16 is a single or double bond, and carbon-23 is a single, double, or triple bond. Various alkyl or haloalkyl substitutions are incorporated at carbon-25. The invention provides pharmaceutically acceptable esters, salts, and prodrugs thereof. Methods for using the compounds for the prevention and treatment of uveitis are also disclosed.